20366-86-3

Basic information

• Product Name: 1H-Purin-6-amine, N-[(2-chlorophenyl)methyl]-
• Synonyms: 1H-Purin-6-amine, N-[(2-chlorophenyl)methyl]-;N-(2-chlorobenzyl)-9H-purin-6-amine;N-(2-chlorobenzyl)-7H-purin-6-amine
• CAS NO: 20366-86-3
• Molecular Formula: C₁₂H₁₀ClN₅
• Molecular Weight: 259.6943
• Mol File: 20366-86-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Purin-6-amine, N-[(2-chlorophenyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Purin-6-amine, N-[(2-chlorophenyl)methyl]-(20366-86-3)
• EPA Substance Registry System: 1H-Purin-6-amine, N-[(2-chlorophenyl)methyl]-(20366-86-3)

Safety Data

• Hazardous Substances Data: 20366-86-3(Hazardous Substances Data)

Usage

Structure

A purine base with a chlorophenylmethyl substituent

Classification

Purine derivative

Uses

Research and drug development, particularly in the study of adenosine receptor antagonists and the treatment of various medical conditions

Potential applications

Medicinal chemistry and the development of pharmaceutical drugs targeting adenosine receptors

Safety

Handle with care and follow proper safety protocols when working with this chemical compound.

Upstream product

• 50-66-8 6-(methylthio)-1H-purine 
• 89-97-4 2-CHLOROBENZYLAMINE 
• 87-42-3 6-chloro-7H-purine 
• 87-42-3 6-chloropurine 

Relevant articles and documents

Design, synthesis and ability of non-gold complexed substituted purine derivatives to inhibit LPS-induced inflammatory response

In order to study the anti-inflammatory activity of novel 6-substituted and 6,9-disubstituted purine derivatives, 20 compounds, L1–10 and W1–10, derived from purine and lacking a gold complex were designed, synthesized and their anti-inflammatory activity was screened. LPS-induced TNF-α, IL-1β, IL-6, PGE2, NO, COX-2 and iNOS mRNA were evaluated, and western blot and NF-κB p65 translocation assay were performed in RAW 264.7 macrophages. Furthermore, carrageenan-induced hind paw edema experiments were performed in mice. Compound L1, L4, W2, and W4 markedly exerted a dose-dependent inhibition of TNF-α, IL-1β, IL-6 and PGE2 release induced by LPS in RAW 264.7 macrophages. Moreover, these compounds strongly inhibited LPS-induced NO, COX-2 and iNOS mRNA in the same cells. Anti-inflammatory activity tests in vivo showed that L1 and L4 were more effective than Au(L3)(PPh3), a known anti-inflammatory agent, at 2–5 h, and W4 was the most effective at 3–5 h after dosing. Thus, W2, W4, and L1, L4, could effectively inhibit LPS-induced inflammatory response in vitro and in vivo suggesting a promising role as anti-inflammatory agents.

9-subsituted-N-(2-chlorobenzyl)purine-6-amine derivative, as well as preparation method and application thereof

The invention discloses a 9-subsituted-N-(2-chlorobenzyl)purine-6-amine derivative. The structure of the derivative is shown in a formula (I), where R is selected from a hydrogen atom, a C1-C4 alkyl group and a substituted or unsubstituted benzyl group, and a substituent on the benzyl group is one or more independently selected from halogen, -CF3, a C1-C4 alkoxy group, a C1-C4 alkyl group and a nitro group; R4 is a substituted or unsubstituted phenyl group or benzyl group, and a substituent on the phenyl group or the benzyl group is one or more of halogen and a methoxy group. Compared with a 6-benyl adenine compound complex gold ion (inhibitor 3), the 9-subsituted-N-(2-chlorobenzyl)purine-6-amine derivative is proved by testing results to have the advantages of higher inflammation factor inhibition rate, higher anti-inflammation activity and potential for use as an anti-inflammation medicament. (The formula (I) is shown in the description.).

Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)

The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity.